

ADVANCES IN IMMUNOLOGY FOR GENE & CELL THERAPY

Friday 28th of March, 2014
Institute of Child Health, University College London
Kennedy Lecture Theatre
Programme

09:00	Registration open – tea/coffee available
09:00	BSGCT Board Meeting, Kennedy Lecture Theatre
09:30	BSGCT AGM – all BSGCT members welcome, Kennedy Lecture Theatre
10:00	Opening address: Andrew Baker and Emma Morris, BSGCT President and Chair of the Organising Committee

Session 1. Vectors: Vector Engineering for Immune Therapies/Immune Responses to Vectors in Gene Therapy

Chairs: Emma Morris and Takis Athanasopoulos
In Association with BioReliance



10:05	Keynote Lecture 1. Prof Amit Nathwani (UCL) INV01: Haemophilia Gene Therapy and managing immune responses to AAV in clinical trials
10:45	S 1.1: Marco Della Peruta (UCL) Development and in vivo evaluation of a liver-specific, tumour-selective recombinant adeno-associated vector to target hepatocellular carcinoma
11:00	S 1.2: George Dickson (Royal Holloway - University of London) Optimised AAV-microdystrophin gene therapy in the GRMD dog model of Duchenne muscular dystrophy: intravenous delivery, long-term expression, functional improvement and absence of adverse cellular immune reactions
11:15	S 1.3: Bobby Gaspar (UCL) Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency
11:30	Keynote Lecture 2. David Williams (Boston Children's Hospital) INV02: An overview of 30 years of hematopoietic stem cell gene therapy

12:15	Lunch/posters/exhibitors
-------	--------------------------

Session 2. British Society for Immunology Special Symposium: Cell Therapy

Chairs: Dave Gilham and Lindy Durrant
In Association with Miltenyi Biotec



13:30	Keynote Lecture 3. Prof Andy Sewell (Cardiff University) INV03: Optimised T-cell receptors for cancer immunotherapy
14:10	SIL01: Shirley Bartido (Memorial Sloan Kettering Cancer Center) Cell therapy products and bioreactors - developing a closed system

14:25	S 2.1/ FB 1: Aliaa Alamoudi (University of Oxford) Regulated antagonism of immune-suppressive molecules in tumours
14:40	S 2.2/ FB 2: Hannah Gornall (The University of Manchester) The mode of activation impacts on the differentiation status of gene modified T cells used in adoptive immunotherapy
14:55	SIL02: Natalie Mount (Cell Therapy Catapult Limited) Accelerating the development of cellular immunotherapies therapies in the UK
15:15	Tea/coffee and posters/exhibitors

Session 3.**Gene Therapy Vaccines****Chairs: Alan Parker and Lynda Coughlan****In Association with Cell Medica**

15:40	Keynote Lecture 4. Prof Sarah Gilbert (The Jenner Institute Laboratories University of Oxford) INV04: Gene therapy vaccines targeting global infection risks
16:20	S 3.1/FB 3: Sean Elias (University of Oxford) Viral vectored blood-stage malaria vaccines induce B cell responses in humans that can be boosted by controlled malaria infection
16:35	S 3.2/ FB 4: Rachel Dakin (University of Glasgow) Efficient transduction of vascular cells by a novel adenovirus serotype 49
16:50	S 3.3: Hawzheen Muhammad (Queen Mary University of London) Development of a novel approach for targeted delivery of siRNA to B lymphocytes with a potential application in cancer

Session 4.**Introduction to Keynote Speaker****Emma Morris****In Association with GE Healthcare**

17:15	Keynote Lecture 5. Bent Jakobsen (Adaptimmune Limited) INV05: Current status and future predictions for TCR-based therapeutics
17:55	Presentation of prizes and closing remarks
18:05	Drinks reception and networking opportunities in The Lamb Public house In Association with Syncona Partners